Program
BC008-1A
A development code. Also written as “BC008-1A 900mg” and “BC008-1A 1200mg”.
Its studies are mostly in Glioblastoma · Esophageal Neoplasms, led by Sichuan Luzhou Buchang Biopharmaceutical.
Furthest: phase 1, since Jan 2, 20252 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Luzhou Buchang Biopharmaceutical | 22 open or running | phase 1since Jan 2, 2025 | Jan 2, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 2, 2025First studies: 2 phase 1 studiesFirst studyNCT06773507, NCT06773481
TargetBeta
TIGIT →read by rule
“BC008-1A is an innovative bispecific antibody targeting TIGIT and PD-1, which is developed by Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.”study text, by rule · the study
Other programs on TIGIT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| domvanalimabrule | Gilead Sciences | phase 3 | 10 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06773507Esophageal Neoplasms · China | 1 | Recruiting | Jun 2026 | 80 |
| NCT06773481Glioma · China | 1 | Recruiting | Jun 2026 | 40 |
How it is read
Names in the registry
- “BC008-1A”, 2 entries
- “BC008-1A 900mg”, 1 entry
- “BC008-1A 1200mg”, 1 entry
Codes read as this program: BC0081A.
Conditions, from the studies’ own filings
- Glioblastoma, 1 study
- Esophageal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.